Clinical catecholamine neurochemistry: a legacy of Julius Axelrod.
1. Discoveries, insights, and concepts that Julius Axelrod introduced about the disposition and metabolism of catecholamines provided the scientific basis and spurred the development of clinical catecholamine neurochemistry. 2. Here, we provide examples of this aspect of Axelrod's scientific legacy.
Goldstein
David S
DS
Clinical Neurocardiology Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20892-1620, USA. goldsteind@ninds.nih.gov
Eisenhofer
Graeme
G
Kopin
Irwin J
IJ
D000224:Addison Disease / Q000209:etiology; D000310:Adrenal Gland Neoplasms / Q000097:blood / Q000175:diagnosis; D000818:Animals; D002395:Catecholamines / Q000097:blood / Q000502:physiology*; D006321:Heart / Q000294:innervation / Q000503:physiopathology; D006801:Humans; D008676:Metanephrine / Q000097:blood; D008734:Methoxyhydroxyphenylglycol / Q000031:analogs & derivatives / Q000032:analysis; D008954:Models, Biological; D009424:Nervous System Physiological Phenomena; D009448:Neurochemistry; D050484:Norepinephrine Plasma Membrane Transport Proteins / Q000032:analysis; D010300:Parkinson Disease / Q000503:physiopathology; D010625:Phenylethanolamine N-Methyltransferase / Q000378:metabolism; D010673:Pheochromocytoma / Q000097:blood / Q000175:diagnosis
D002395:Catecholamines; D050484:Norepinephrine Plasma Membrane Transport Proteins; C493227:SLC6A2 protein, human; D008676:Metanephrine; D008734:Methoxyhydroxyphenylglycol; D010625:Phenylethanolamine N-Methyltransferase; C010117:3,4-dihydroxyphenylglycol